Spero Therapeutics closes exclusive license agreement with GSK for tebipenem HBr

Spero Therapeutics, Inc.

Received $66 million upfront payment from GSK under the exclusive license agreement.
GSK affiliate purchased 7,450,000 shares of Spero common stock for approximately $9 million.
Spero eligible for up to $525 million in development, sales, and commercial milestones plus tiered royalties.
Spero will conduct a follow-up Phase 3 trial; GSK responsible for further development and commercialization outside Meiji Seika territories.
GSK granted exclusive license to develop and commercialize tebipenem HBr in all territories except Japan and certain Asian countries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.